Optimizing the Long-Term Therapy with Eculizumab (ECU) for Atypical Hemolytic Uremic Syndrome (aHUS)

Indian J Pediatr. 2024 Feb;91(2):205. doi: 10.1007/s12098-023-04817-0. Epub 2023 Sep 30.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Atypical Hemolytic Uremic Syndrome* / drug therapy
  • Complement Factor H
  • Humans

Substances

  • eculizumab
  • Antibodies, Monoclonal, Humanized
  • Complement Factor H